HLB Therapeutics Co.,Ltd. HLB Therapeutics Co.,Ltd.

HLB Therapeutics Co.,Ltd.

115450

Hisse Senetlerindeki Sıralama #18257
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Hisse Fiyatı
$2.02
Piyasa Değeri
$190.66M
Değişim (1 gün)
7.96%
Değişim (1 yıl)
-1.16%
Ülke
KR
Ticaret HLB Therapeutics Co.,Ltd. (115450)

Kategori

Healthcare
HLB Therapeutics Co.,Ltd. (115450) için gelir
Oct 2026 itibarıyla gelir TTM: 0
HLB Therapeutics Co.,Ltd. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) 0'dir. 2026 yılında şirketin geliri 0 önceki yıla eşit 2026 yılındaki 0 gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
HLB Therapeutics Co.,Ltd. için 2016 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
2025 $48.26M 29.15%
2024 $37.36M -10.01%
2023 $41.52M 23.56%
2022 $33.60M -8.35%
2021 $36.66M -7.29%
2020 $39.54M -22.56%
2019 $51.06M 30.46%
2018 $39.14M 143.21%
2017 $16.09M 9.57%
2016 $14.69M 0.00%
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
$12.62B -
US
$2.23B -
US
$15.74B -
AU
$10.11B -
BE
$6.02B -
NL